



PATENT
Attorney Docket No. 063779-5001
(Formerly 11438-004-999)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: F. Myhren *et al.*

Application No.: 10/662,441

Confirmation No.: 9826

Filed: September 16, 2003

Group Art Unit: 1617

For: METHODS OF TREATING DISORDERS
USING LIPOPHILIC DERIVATIVES

Examiner: B. Badeo

REVOCATION OF ORIGINAL POWER OF ATTORNEY
AND GRANT OF NEW POWER OF ATTORNEY

Commissioner of Patents
U.S. Patent and Trademark Office
Alexandria, VA 22314

Sir:

Clavis Pharma AS owners of the entire right, title, and interest in, to and under the invention described and claimed in the above-identified patent application, hereby revokes all previous Powers of Attorney in U.S. Patent Application No. 10/662,441 and any application leading thereto, and hereby grants in respect of said patent application(s), Power of Attorney to the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to transact all business in the U.S. Patent and Trademark Office connected therewith.

Clavis Pharma AS further direct that all correspondence be addressed to the Customer Number given below:

Customer Number: 009629

Please direct all telephone inquiries to:

Dean L. Fanelli
Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Telephone: (202) 739-5656
Facsimile: (202) 739-3001

An assignment of the entire interest in the above-identified subject application was filed in the parent application, 10/116,358, which issued as U.S. Patent Number 6,762,175 at Reel Number 015574 and Frame Number 0299.

We hereby declare that all statements made herein of our own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001. Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Clavis Pharma AS

By: Name: Finn Olsen
Title: VP Chem Pharm R&D
Date: 21. 11. 2016


Tom E. Pike
Chief Executive Officer



PATENT
ATTORNEY DOCKET NO.: 063779-5001
(Formerly 11438-004-999)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Myhren *et al.*) Confirmation No.: 9826
)
Application No.: 10/662,441) Group Art Unit: 1617
)
Filed: September 16, 2003) Examiner: B. BADIO
)
)
For: METHODS OF TREATING DISORDERS)
USING LIPOPHILIC DERIVATIVES)

Commissioner of Patents and Trademarks
U.S. Patent and Trademark Office
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

CHANGE OF CORRESPONDENCE ADDRESS

Please change the correspondence address from that listed in the original Declaration and Power of Attorney in this application to:

Customer Number 009629

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP


Dean L. Fanelli Reg. No. 43,210

Dated: November 30, 2006
Morgan, Lewis & Bockius LLP
1111 Pennsylvania Ave., NW
Washington, DC 20004
Tel: 202.739.3000
Fax: 202.739.3001